Cargando…

Advances in genetics Volume 82 /

The field of genetics is rapidly evolving, and new medical breakthroughs are occurring as a result of advances in our knowledge of genetics. This series continually publishes important reviews of the broadest interest to geneticists and their colleagues in affiliated disciplines. * Includes methods...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Friedmann, Theodore, Dunlap, Jay C., Goodwin, Stephen
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Amsterdam, Netherlands : Elsevier, �2013.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000Ma 4500
001 SCIDIR_ocn849940856
003 OCoLC
005 20231117044906.0
006 m o d
007 cr cn|||||||||
008 130611s2013 ne a ob 001 0 eng d
040 |a E7B  |b eng  |e pn  |c E7B  |d OCLCF  |d OCLCO  |d EBLCP  |d YDXCP  |d OPELS  |d UKDOC  |d DEBSZ  |d OCLCQ  |d DEBBG  |d D6H  |d OCLCE  |d UKBTH  |d OCLCQ  |d SFB  |d OCLCO  |d OCLCQ  |d OCLCO 
019 |a 851315817  |a 1084726866  |a 1127137787 
020 |a 0124078028 
020 |a 9780124078024 
035 |a (OCoLC)849940856  |z (OCoLC)851315817  |z (OCoLC)1084726866  |z (OCoLC)1127137787 
050 4 |a QH430  |b .A38 2013eb 
082 0 4 |a 575.5  |2 23 
245 0 0 |a Advances in genetics  |n Volume 82 /  |c edited by Theodore Friedmann, Jay C. Dunlap, Stephen Goodwin. 
260 |a Amsterdam, Netherlands :  |b Elsevier,  |c �2013. 
300 |a 1 online resource (vii, 111 pages) :  |b illustrations (some color) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
504 |a Includes bibliographical references and index. 
588 0 |a Online resource; title from title page (ebrary, viewed June 11, 2013). 
505 0 |a Front Cover; Advances in Genetics; Copyright; Contents; Contributors; Chapter One: The Repair and Signaling Responses to DNA Double-Strand Breaks; 1. Introduction; 2. Formation of DSBs; 3. Mechanisms of DSB Rejoining; 3.1. Homologous recombination; 3.2. Nonhomologous end-joining; 3.2.1. DNA-PK: The first complex formed during NHEJ; 3.2.2. DSB end processing during NHEJ; 3.2.3. DNA ligase IV, XRCC4, and XLF, the second NHEJ complex; 3.3. Additional end-joining processes; 4. DNA Damage Response Signaling; 4.1. The assembly process; 4.2. Factors regulating the recruitment of 53BP1 
505 8 |a 4.3. Assembly of the BRCA1 and the RAP80/Abraxas/BRCC36 complex4.4. Involvement of noncoding RNAs; 5. Functions of the DDR Assembly; 5.1. Signaling to the checkpoint machinery; 5.2. The repair of DSB located within heterochromatin; 5.3. Transcriptional arrest at transcriptionally active DSBs; 5.4. Impact of additional chromatin changes at DSBs; 5.4.1. Role for HP1 in the DDR; 5.4.2. The involvement of CHD4-NuRD in the DDR; 5.4.3. The involvement of Tip60 and the NuA4 complex in the DDR; 5.4.4. The involvement of SNF2H, ACF1, and RNF20-RNF40 in the DDR 
505 8 |a 6. Regulation of DSB Repair Pathway Choice6.1. Impact of cell cycle phase and resection; 6.2. Role of 53BP1; 6.3. Model for the interface between NHEJ and HR; 7. Contribution of Defects in DSB Rejoining Processes to Human Disease; 8. Concluding Remarks; References; Chapter Two: Biological Activity and Biotechnological Aspects of Locked Nucleic Acids; 1. Brief Introduction; 2. Chemistry and Structure; 2.1. LNA characteristics and structure; 2.2. LNA analogues and conjugates; 3. Biological Activity of LNA-Containing ONs; 3.1. Antisense LNA; 3.1.1. Affinity and potency 
505 8 |a 3.1.2. Cellular uptake and gymnosis3.1.2.1. Uptake mechanisms; 3.1.2.2. Comparing cellular uptake and antisense efficiency; 3.2. siLNA: Improving siRNA performance by LNA modification; 3.2.1. Tolerance for LNA modification; 3.2.2. Enhancing siRNA activity and specificity by LNA modification; 3.2.3. Enhancing siRNA nuclease resistance by LNA modification; 3.2.4. Reducing siRNA immunogenicity by LNA modification; 3.2.5. Applying siLNA in vivo; 3.3. LNA and splice-switching ONs; 3.3.1. Splice switching; 3.3.2. LNA in SSOs; 3.4. LNA in antigene reagents; 3.4.1. LNA in triplex-forming ONs 
505 8 |a 3.4.1.1. LNA-modified pyrimidine TFOs3.4.1.2. Intracellular effects of LNA-modified pyrimidine TFOs; 3.4.2. LNA in double-strand-invading ONs; 3.4.2.1. LNA-containing clamp ONs; 3.4.2.2. Invader-LNA; 3.4.2.3. Zorro-LNA; 3.4.2.4. ``Linear� � antigene LNA ONs; 4. LNA Pharmacology; 4.1. Pharmacokinetics; 4.1.1. Delivery and bioavailability; 4.1.2. Tissue distribution; 4.2. Pharmacodynamics; 4.2.1. Targeting ApoB-100; 4.2.2. Targeting PCSK9; 4.2.3. Targeting miR-122; 4.2.4. LNA pharmacology in malignant tissues; 5. LNA in Biotechnology; 5.1. LNA in primers and probes; 5.1.1. LNA primers 
520 |a The field of genetics is rapidly evolving, and new medical breakthroughs are occurring as a result of advances in our knowledge of genetics. This series continually publishes important reviews of the broadest interest to geneticists and their colleagues in affiliated disciplines. * Includes methods for testing with ethical, legal, and social implications* Critically analyzes future. 
546 |a English. 
650 0 |a Genetics. 
650 6 |a G�en�etique.  |0 (CaQQLa)201-0069234 
650 7 |a genetics.  |2 aat  |0 (CStmoGRI)aat300138822 
650 7 |a Genetics  |2 fast  |0 (OCoLC)fst00940117 
700 1 |a Friedmann, Theodore. 
700 1 |a Dunlap, Jay C. 
700 1 |a Goodwin, Stephen. 
776 0 8 |i Online version:  |t Advances in genetics Volume 82.  |d Amsterdam, Netherlands : Elsevier, �2013  |w (OCoLC)1084726866 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/book/9780124076761  |z Texto completo